Connect with us

News

Study to explore effects of CBD on the heart

Published

4 years ago

on

The study will examine the effects of CBD on targeted cardiology markers

A new study will investigate the potential effects of CBD on heart function for the first time. 

Researchers at Mount Sinai Medical Hospital in New York will examine the effects that CBD may have on cardiology markers in a six-month clinical trial which may prove “groundbreaking” for the field.

The clinical trial consists of two studies conducted by Dr David Harnick, a prominent cardiologist and assistant professor of medicine and cardiology at Mount Sinai Medical Hospital.

It has been constructed to gather data that will help in the deeper understanding of the effects CBD has on the body.

US health and wellness CBD company, HempFusion has announced that its products had been chosen as the exclusive provider by Dr Harnick, who commented: “Studying the potential effects that CBD may have on cardiology markers may potentially unlock some of the scientific mysteries that exist today. 

“We know that there is evidence that CBD may have beneficial effects on the body, but the exact scope of those effects remains to be determined. There have been no published randomised prospective controlled trials evaluating the effects of CBD on these cardiac markers, so this research may prove to be groundbreaking.” 

The study is expected to commence in March 2021 and it will be one-of-a-kind in the area of the effects of CBD on targeted cardiology markers.

Dr. Harnick chose HempFusion for its rigorous regulatory standards, toxicology studies for safety, and adherence to quality control.

The company also recently partnered with ValidCare as a co-sponsor alongside 12 other companies in the CBD space, collaborated in an industry-wide Human Observational liver and male reproductive toxicology studies, which explore the effects that full-spectrum hemp-derived CBD has on the liver.

“This is the second clinical trial HempFusion is proudly participating in,” HempFusion Wellness CEO Jason Mitchel, N.D. said.

“We are committed to furthering research in the area of hemp-derived CBD and this study [with Dr. Harnick] is a significant expansion of our efforts that reinforces our continued focus on the safe and effective use of hemp-derived CBD products,” he added. 

The CBD used in these trials is the same product the company offers to the public.

Related Topics:

Sarah Sinclair is an award-winning freelance journalist covering health, drug policy and social affairs. She is one of the few UK reporters specialising in medical cannabis policy and as the former editor of Cannabis Health has covered developments in the European cannabis sector extensively, with a focus on patients and consumers. She continues to report on cannabis-related health and policy for Forbes, Cannabis Health and Business of Cannabis and has written for The i Paper, Byline Times, The Lead, Positive News, Leafie & others. Sarah has an NCTJ accreditation and an MA in Journalism from the University of Sunderland and has completed additional specialist training through the Medical Cannabis Clinicians Society in the UK. She has spoken at leading industry events such as Cannabis Europa.

Trending

Cannabis Health is a journalist-led news site. Any views expressed by interviewees or commentators do not reflect our own. All content on this site is intended for educational purposes, please seek professional medical advice if you are concerned about any of the issues raised.

Copyright © 2024 PP Intelligence Ltd.